Systems Medicine (SML) initially began its relationship with OmniComm through OmniComm’s CRO preferred program and then selected OmniComm as its electronic data capture (EDC) vendor of choice for its Phase II study.
Stephen Johnson, COO of OmniComm, said: “Research organizations are looking at EDC as a strategic imperative to help maximize their investments in today’s highly competitive clinical research environment.
“OmniComm is privileged to be partnering with companies like SML that are delivering cutting edge cancer treatments to the marketplace. It gives us great satisfaction to know that our TrialMaster EDC solution helps to speed up that process.”